关键免疫反应蛋白抑制因子的最新发展给自身免疫性疾病的治疗带来了革命性的变化,这些免疫调节剂包括单克隆抗体和受体拮抗剂。然而,就治疗方法来看,这些新制剂并非无副作用和并发症。尤其是已经报道的抗肿瘤坏死因子α(TNFα)可能会增加患淋巴组织增生性疾病、感染及脉管炎的概率。本文评估了几个机构的18例免疫调节剂相关的淋巴组织增生性 Recent developments in key immunoreactive protein inhibitors have revolutionized the treatment of autoimmune diseases, including both monoclonal and receptor antagonists. However, in terms of treatment, these new formulations are not without side effects and complications. In particular, the reported anti-tumor necrosis factor alpha (TNFa) may increase the probability of having lymphoproliferative diseases, infections and vasculitis. This article assesses 18 immunomodulator-associated lymphoproliferative properties in several institutions